Skip to content

Genmab

US · GMAB #860 by market cap Listed 2019
50.60 -0.75 -1.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.3 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
61.61% -0.25pp
Institutions
627 -3
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund42.53%
Hedge Fund12.90%
Government Pension Fund1.95%
VC/PE Fund1.51%
Sovereign Wealth Fund1.25%
Individual/Insider1.10%
Private Company0.66%
Public Company0.53%
Insurance Company0.21%
Other37.35%

Top holders as of 2026-09-30

BlackRock 6.81% · 43.13M sh
Orbis Investment Management Limited 6.67% · 42.23M sh
Darwin Global Management Limited 5.71% · 36.15M sh
Vanguard Capital Management, LLC 3.72% · 23.52M sh
Paradigm Biocapital Advisors LP 2.23% · 14.14M sh
Wellington Management Group 2.08% · 13.17M sh
AllianceBernstein 2.02% · 12.76M sh
Baillie Gifford 1.39% · 8.81M sh
Amundi Asset Management 1.34% · 8.02M sh
Norges Bank Investment Management 1.23% · 7.76M sh
Harding Loevner LP 1.33% · 7.95M sh
Deerfield Management Company, L.P. 1.08% · 6.87M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

3 filings tracked · 0 buys · 3 sells

NameRoleStake
Judith Klimovsky Chief Development Officer 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Judith Klimovsky Chief Development Officer Intent to Sell (Form 144) -1,265 $556.78
2025-06-16 Judith Klimovsky Chief Development Officer Intent to Sell (Form 144) -1,300 $51.69
2024-02-29 Judith Klimovsky Chief Development Officer Intent to Sell (Form 144) -1,200 $27.77

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:56:12 · For reference only, not investment advice and not tailored to your situation.

Genmab discussion 0 comments

Add a comment